UK NEQAS for H&I Schemes & Rationale

SCHEME 1A – HLA PHENOTYPING
To assess participants’ ability to use serological and supplementary methods to correctly identify HLA specificities.

SCHEME 1B – HLA-B27 TESTING
To assess participants’ ability to correctly determine HLA-B27/B2708/B*27 status.

SCHEME 2A – CYTOTOXIC CROSSMATCHING
To assess participants’ ability to correctly determine cell/serum cytotoxic crossmatch status.

SCHEME 2B – CROSSMATCHING BY FLOW CYTOMETRY
To assess participants’ ability to correctly determine cell/serum flow cytometry crossmatch status.

SCHEME 3 – HLA ANTIBODY SPECIFICITY ANALYSIS
To assess participants’ ability to correctly determine HLA antibody specificities.

SCHEME 4A1 – DNA HLA TYPING AT 1ST FIELD RESOLUTION
To assess participants’ ability to correctly determine HLA alleles at the 1st field level (formerly known as low resolution or 2-digit typing).

SCHEME 4A2 – DNA HLA TYPING TO 2ND FIELD RESOLUTION
To assess participants’ ability to correctly determine HLA alleles to the 2nd field level (formerly known as high resolution or 4-digit typing).

SCHEME 4B – ABO GROUPING BY DNA-BASED METHODS
To assess participants’ ability to correctly determine ABO blood groups by DNA-based methods.

SCHEME 5A – HFE TYPING
To assess participants’ ability to correctly determine HFE mutations.

SCHEME 5B – INTERPRETATIVE: HFE GENOTYPE AND HEREDITARY HAEMOCHROMATOSIS
To assess participants’ ability to make an accurate, clear, concise and timely clinical report, appropriate for the range of clinical staff involved in a patient’s care and treatment, given HFE genotype and other relevant clinical information.

SCHEME 6 – “HLA” ANTIBODY DETECTION
To assess participants’ ability to correctly determine the likely presence of HLA antibodies.

SCHEME 7 – HLA-B*57:01 TYPING FOR DRUG HYPERSENSITIVITY
To assess participants’ ability to correctly determine HLA-B*57:01 status.

SCHEME 8 – HLA AND DISEASE TYPING FOR HLA-DR/DQ/DP ONLY
To assess participants’ ability to determine HLA-DR/DQ/DP allele families/alleles.

EDUCATIONAL SCHEME and INTERPRETIVE EDUCATION SCHEME
To provide participants’ with either a variety of interesting samples to test and/or clinical scenarios that offer a beneficial educational element.

PILOT SCHEMES – HPA GENOTYPING, KIR GENOTYPING and MICA GENOTYPING
To provide participants’ with samples for HPA Genotyping, KIR Genotyping and MICA Genotyping. These will not be assessed.